Deciphera says its drug for rare joint tumor succeeded in a PhIII study, will submit to FDA
Deciphera Pharmaceuticals’ experimental treatment for tenosynovial giant cell tumor passed a pivotal study, setting the biotech up to go for its second drug approval.
In the Phase III MOTION study, 123 patients who were not recommended to receive surgery received either vimseltinib twice a week or placebo. After 24 weeks, 40% of patients who received vimseltinib saw their tumors shrink by at least 30%, compared to none of the patients in the placebo arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
